Cargando…

National and provincial burden of varicella disease and cost-effectiveness of childhood varicella vaccination in China from 2019 to 2049: a modelling analysis

BACKGROUND: In China, varicella is the third most frequently reported vaccine-preventable infectious disease after tuberculosis and influenza, and imposes a heavy burden on families and society. To inform future immunization policy, we investigated disease burden of varicella in China and explored c...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Huangyufei, Zhang, Haijun, Ma, Chao, Zhang, Haonan, Yin, Dapeng, Fang, Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918754/
https://www.ncbi.nlm.nih.gov/pubmed/36785851
http://dx.doi.org/10.1016/j.lanwpc.2022.100639
_version_ 1784886655177457664
author Feng, Huangyufei
Zhang, Haijun
Ma, Chao
Zhang, Haonan
Yin, Dapeng
Fang, Hai
author_facet Feng, Huangyufei
Zhang, Haijun
Ma, Chao
Zhang, Haonan
Yin, Dapeng
Fang, Hai
author_sort Feng, Huangyufei
collection PubMed
description BACKGROUND: In China, varicella is the third most frequently reported vaccine-preventable infectious disease after tuberculosis and influenza, and imposes a heavy burden on families and society. To inform future immunization policy, we investigated disease burden of varicella in China and explored cost-effectiveness of different varicella vaccination strategies at national and provincial levels. METHODS: A dynamic transmission model was developed to assess disease burden of varicella and the impact of varicella vaccination in China. A cost-effectiveness analysis of three alternative vaccination strategies in China's National Immunization Program (NIP) compared with no vaccination was conducted. Scenario analyses and sensitivity analyses were performed to check the robustness of the results. FINDINGS: It was estimated that 3.35 million new varicella cases occurred in 2019, more than three times of 982 thousand cases officially reported from National Notifiable Infectious Disease Surveillance System (NNIDSS). The under-reported rate was approximately 71%. The economic analysis revealed that from the societal perspective, the incremental cost-effectiveness ratio (ICER) for one dose of varicella vaccination in NIP was US$ 2357 per QALY at the national level and it was cost-effective in 22 of 31 provinces. The ICER for one dose varicella vaccination plus a mass catch-up for unvaccinated children aged 2–11 years old would be US$ −5260 per QALY, cost-saving at the national level. The one dose plus mass catch-up NIP strategy was also cost-saving in 24 of the 31 provinces. INTERPRETATION: Varicella incident cases were substantially under-reported in China. Varicella vaccination in the NIP could significantly contribute to reducing the burden of varicella disease. From the societal perspective, including varicella vaccination into China's NIP was highly cost-effective at the national level and in most provinces. FUNDING: 10.13039/100000865Bill & Melinda Gates Foundation.
format Online
Article
Text
id pubmed-9918754
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-99187542023-02-12 National and provincial burden of varicella disease and cost-effectiveness of childhood varicella vaccination in China from 2019 to 2049: a modelling analysis Feng, Huangyufei Zhang, Haijun Ma, Chao Zhang, Haonan Yin, Dapeng Fang, Hai Lancet Reg Health West Pac Articles BACKGROUND: In China, varicella is the third most frequently reported vaccine-preventable infectious disease after tuberculosis and influenza, and imposes a heavy burden on families and society. To inform future immunization policy, we investigated disease burden of varicella in China and explored cost-effectiveness of different varicella vaccination strategies at national and provincial levels. METHODS: A dynamic transmission model was developed to assess disease burden of varicella and the impact of varicella vaccination in China. A cost-effectiveness analysis of three alternative vaccination strategies in China's National Immunization Program (NIP) compared with no vaccination was conducted. Scenario analyses and sensitivity analyses were performed to check the robustness of the results. FINDINGS: It was estimated that 3.35 million new varicella cases occurred in 2019, more than three times of 982 thousand cases officially reported from National Notifiable Infectious Disease Surveillance System (NNIDSS). The under-reported rate was approximately 71%. The economic analysis revealed that from the societal perspective, the incremental cost-effectiveness ratio (ICER) for one dose of varicella vaccination in NIP was US$ 2357 per QALY at the national level and it was cost-effective in 22 of 31 provinces. The ICER for one dose varicella vaccination plus a mass catch-up for unvaccinated children aged 2–11 years old would be US$ −5260 per QALY, cost-saving at the national level. The one dose plus mass catch-up NIP strategy was also cost-saving in 24 of the 31 provinces. INTERPRETATION: Varicella incident cases were substantially under-reported in China. Varicella vaccination in the NIP could significantly contribute to reducing the burden of varicella disease. From the societal perspective, including varicella vaccination into China's NIP was highly cost-effective at the national level and in most provinces. FUNDING: 10.13039/100000865Bill & Melinda Gates Foundation. Elsevier 2022-11-11 /pmc/articles/PMC9918754/ /pubmed/36785851 http://dx.doi.org/10.1016/j.lanwpc.2022.100639 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Articles
Feng, Huangyufei
Zhang, Haijun
Ma, Chao
Zhang, Haonan
Yin, Dapeng
Fang, Hai
National and provincial burden of varicella disease and cost-effectiveness of childhood varicella vaccination in China from 2019 to 2049: a modelling analysis
title National and provincial burden of varicella disease and cost-effectiveness of childhood varicella vaccination in China from 2019 to 2049: a modelling analysis
title_full National and provincial burden of varicella disease and cost-effectiveness of childhood varicella vaccination in China from 2019 to 2049: a modelling analysis
title_fullStr National and provincial burden of varicella disease and cost-effectiveness of childhood varicella vaccination in China from 2019 to 2049: a modelling analysis
title_full_unstemmed National and provincial burden of varicella disease and cost-effectiveness of childhood varicella vaccination in China from 2019 to 2049: a modelling analysis
title_short National and provincial burden of varicella disease and cost-effectiveness of childhood varicella vaccination in China from 2019 to 2049: a modelling analysis
title_sort national and provincial burden of varicella disease and cost-effectiveness of childhood varicella vaccination in china from 2019 to 2049: a modelling analysis
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918754/
https://www.ncbi.nlm.nih.gov/pubmed/36785851
http://dx.doi.org/10.1016/j.lanwpc.2022.100639
work_keys_str_mv AT fenghuangyufei nationalandprovincialburdenofvaricelladiseaseandcosteffectivenessofchildhoodvaricellavaccinationinchinafrom2019to2049amodellinganalysis
AT zhanghaijun nationalandprovincialburdenofvaricelladiseaseandcosteffectivenessofchildhoodvaricellavaccinationinchinafrom2019to2049amodellinganalysis
AT machao nationalandprovincialburdenofvaricelladiseaseandcosteffectivenessofchildhoodvaricellavaccinationinchinafrom2019to2049amodellinganalysis
AT zhanghaonan nationalandprovincialburdenofvaricelladiseaseandcosteffectivenessofchildhoodvaricellavaccinationinchinafrom2019to2049amodellinganalysis
AT yindapeng nationalandprovincialburdenofvaricelladiseaseandcosteffectivenessofchildhoodvaricellavaccinationinchinafrom2019to2049amodellinganalysis
AT fanghai nationalandprovincialburdenofvaricelladiseaseandcosteffectivenessofchildhoodvaricellavaccinationinchinafrom2019to2049amodellinganalysis